Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)

Inclusion Criteria:

* Signed written informed consent consistent with Chinese Good Clinical Practice.
* Male or female patients of age \>/= 18 years at the time of informed consent.
* Patients with relapsed/refractory AML ineligible for conventional or intensive treatment.
* Eastern Cooperative Oncology Group performance status score 0 - 2 at screening.
* Life expectancy of at least 3 months.
* Adequate hepatic, renal and metabolic function parameters: Serum total bilirubin ≤1.5 x upper limit of normal, aspartate transaminase (AST) , alanine transaminase (ALT) ≤2.5 x upper limit of normal; Creatinine clearance rate ≥60ml/min, Serum creatinine ≤1.0 x upper limit of normal; Relatively normal ECG(electrocardiogram), QTc\<450 ms(male) ,QTc\<470 ms(female); LVEF\>50%.
* Patients who can comply with the trial and follow-up procedures.

Exclusion Criteria:

* Patients had received cafusertib hydrochloride or other PLK inhibitors.
* Patients with APL.
* Patients with central nervous system leukemia.
* Need to continue using cytokine therapy at screening.
* Patients participated in other clinical trials within 4 weeks prior to enrollment.
* Patient with severe infection.
* Patients with myocardial infarction had occurred within six months prior to enrollment.
* Severe heart disease, including NYHA class II cardiac dysfunction and above.
* Patients with HIV infection or acute and chronic viral hepatitis.
* Severe gastrointestinal disorders (bleeding, infection, obstruction or greater than grade 1 diarrhea).
* A previous history of neurological or psychiatric disorders, including epilepsy or dementia.
* Concomitant medications with CYP3A4 inhibitors, inducers or substrates; Women pregnant or breast feeding.
* Subject is thought unfit for this study by investigator.